478 related articles for article (PubMed ID: 21311083)
1. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes.
Fonarow GC; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Grau-Sepulveda MV; Olson DM; Hernandez AF; Peterson ED; Schwamm LH
Circulation; 2011 Feb; 123(7):750-8. PubMed ID: 21311083
[TBL] [Abstract][Full Text] [Related]
2. Emergency medical service hospital prenotification is associated with improved evaluation and treatment of acute ischemic stroke.
Lin CB; Peterson ED; Smith EE; Saver JL; Liang L; Xian Y; Olson DM; Shah BR; Hernandez AF; Schwamm LH; Fonarow GC
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):514-22. PubMed ID: 22787065
[TBL] [Abstract][Full Text] [Related]
3. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.
Schwamm LH; Ali SF; Reeves MJ; Smith EE; Saver JL; Messe S; Bhatt DL; Grau-Sepulveda MV; Peterson ED; Fonarow GC
Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):543-9. PubMed ID: 24046398
[TBL] [Abstract][Full Text] [Related]
4. EMS mythology. EMS myth #2. Thombolytic therapy is the standard of care for acute ischemic stroke.
Bledsoe BE
Emerg Med Serv; 2003 Apr; 32(4):63-5. PubMed ID: 12705219
[No Abstract] [Full Text] [Related]
5. Protocol adherence and safety of intravenous thrombolysis after telephone consultation with a stroke center.
Uchino K; Massaro L; Jovin TG; Hammer MD; Wechsler LR
J Stroke Cerebrovasc Dis; 2010; 19(6):417-23. PubMed ID: 21051004
[TBL] [Abstract][Full Text] [Related]
6. Use of tissue-type plasminogen activator before and after publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke.
Messé SR; Fonarow GC; Smith EE; Kaltenbach L; Olson DM; Kasner SE; Schwamm LH
Circ Cardiovasc Qual Outcomes; 2012 May; 5(3):321-6. PubMed ID: 22550132
[TBL] [Abstract][Full Text] [Related]
7. Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative.
Fonarow GC; Smith EE; Saver JL; Reeves MJ; Hernandez AF; Peterson ED; Sacco RL; Schwamm LH
Stroke; 2011 Oct; 42(10):2983-9. PubMed ID: 21885841
[TBL] [Abstract][Full Text] [Related]
8. Influence of gender on outcomes after intra-arterial thrombolysis for acute ischemic stroke.
Shah SH; Liebeskind DS; Saver JL; Starkman S; Vinuela F; Duckwiler G; Jahan R; Kim D; Sanossian N; Vespa P; Ovbiagele B
Neurology; 2006 Jun; 66(11):1745-6. PubMed ID: 16769954
[TBL] [Abstract][Full Text] [Related]
9. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH
JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513
[TBL] [Abstract][Full Text] [Related]
10. Utilization of intravenous tissue plasminogen activator for ischemic stroke: are there sex differences?
Allen NB; Myers D; Watanabe E; Dostal J; Sama D; Goldstein LB; Lichtman JH
Cerebrovasc Dis; 2009; 27(3):254-8. PubMed ID: 19176959
[TBL] [Abstract][Full Text] [Related]
11. Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke.
Xian Y; Xu H; Lytle B; Blevins J; Peterson ED; Hernandez AF; Smith EE; Saver JL; Messé SR; Paulsen M; Suter RE; Reeves MJ; Jauch EC; Schwamm LH; Fonarow GC
Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28096207
[TBL] [Abstract][Full Text] [Related]
12. Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke.
Kamal N; Sheng S; Xian Y; Matsouaka R; Hill MD; Bhatt DL; Saver JL; Reeves MJ; Fonarow GC; Schwamm LH; Smith EE
Stroke; 2017 Apr; 48(4):946-954. PubMed ID: 28228574
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Thai patients with acute ischemic stroke after intravenous thrombolysis.
Dharmasaroja PA; Dharmasaroja P; Muengtaweepongsa S
J Neurol Sci; 2011 Jan; 300(1-2):74-7. PubMed ID: 20937509
[TBL] [Abstract][Full Text] [Related]
14. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
Wolfe T; Suarez JI; Tarr RW; Welter E; Landis D; Sunshine JL; Zaidat OO
J Stroke Cerebrovasc Dis; 2008; 17(3):121-8. PubMed ID: 18436152
[TBL] [Abstract][Full Text] [Related]
15. Rapid neurological recovery after intravenous tissue plasminogen activator in stroke: prognostic factors and outcome.
Machumpurath B; Davis SM; Yan B
Cerebrovasc Dis; 2011; 31(3):278-83. PubMed ID: 21178353
[TBL] [Abstract][Full Text] [Related]
16. Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan.
Yang FC; Lin CC; Hsueh CJ; Lee JT; Hsu CH; Lee KW; Peng GS
Ann Vasc Surg; 2010 Nov; 24(8):1117-24. PubMed ID: 21035704
[TBL] [Abstract][Full Text] [Related]
17. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital.
Hsu YC; Sung SF; Ong CT; Wu CS; Su YH
Acta Neurol Taiwan; 2009 Mar; 18(1):14-20. PubMed ID: 19537569
[TBL] [Abstract][Full Text] [Related]
18. Treatment of acute ischemic stroke: intravenous and endovascular therapies.
Jahan R; Vinuela F
Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):375-87. PubMed ID: 19379062
[TBL] [Abstract][Full Text] [Related]
19. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator?
Hassan AE; Zacharatos H; Hassanzadeh B; El-Gengaihy A; AlKawi A; Shhadeh A; Kirmani JF
J Stroke Cerebrovasc Dis; 2010 Mar; 19(2):116-20. PubMed ID: 20189087
[TBL] [Abstract][Full Text] [Related]
20. Administration of tissue plasminogen activator for acute ischemic stroke in a rural Wisconsin hospital.
Charipar R; Charipar E
WMJ; 2008 Jul; 107(4):176-80. PubMed ID: 18702433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
